Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Literature DB >> 30948490

Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Yasutaka Fukuda¹, Marito Araki², Kouji Yamamoto^3,4, Soji Morishita², Tadaaki Inano¹, Kyohei Misawa¹, Tomonori Ochiai¹, Yoko Edahiro¹, Misa Imai^1,5, Hajime Yasuda¹, Akihiko Gotoh¹, Akimichi Ohsaka², Norio Komatsu⁶.

Abstract

Entities: Disease

Year: 2019 PMID： 30948490 PMCID： PMC6821608 DOI： 10.3324/haematol.2018.208876

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.

Authors: Alexander Sidelmann Christensen; Jonas Bech Møller; Hans Carl Hasselbalch
Journal: Leuk Res Date: 2014-02-04 Impact factor: 3.156

2. Myeloproliferative neoplasms cause glomerulopathy.

Authors: Samar M Said; Nelson Leung; Sanjeev Sethi; Lynn D Cornell; Mary E Fidler; Joseph P Grande; Sandra Herrmann; Ayalew Tefferi; Vivette D D'Agati; Samih H Nasr
Journal: Kidney Int Date: 2011-06-08 Impact factor: 10.612

Review 3. The role of cytokines in the initiation and progression of myelofibrosis.

Authors: Hans C Hasselbalch
Journal: Cytokine Growth Factor Rev Date: 2013-02-13 Impact factor: 7.638

Review 4. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Authors: S Koschmieder; T I Mughal; H C Hasselbalch; G Barosi; P Valent; J-J Kiladjian; G Jeryczynski; H Gisslinger; J S Jutzi; H L Pahl; R Hehlmann; A Maria Vannucchi; F Cervantes; R T Silver; T Barbui
Journal: Leukemia Date: 2016-02-08 Impact factor: 11.528

Review 5. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors: Elisa Rumi; Mario Cazzola
Journal: Blood Date: 2016-12-27 Impact factor: 22.113

Review 6. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Authors: William Vainchenker; Robert Kralovics
Journal: Blood Date: 2016-12-27 Impact factor: 22.113

7. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Authors: C Marty; C Lacout; N Droin; J-P Le Couédic; V Ribrag; E Solary; W Vainchenker; J-L Villeval; I Plo
Journal: Leukemia Date: 2013-04-05 Impact factor: 11.528

8. Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics.

Authors: G Barosi; M Cazzola; F Frassoni; E Orlandi; M Stefanelli
Journal: Br J Haematol Date: 1981-06 Impact factor: 6.998

3. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Authors: Ken Ogasawara; William B Smith; Christine Xu; Jian Yin; Maria Palmisano; Gopal Krishna
Journal: Cancer Chemother Pharmacol Date: 2020-05-24 Impact factor: 3.333

3 in total